Alterations in the proportions of NKR+ T-cells in MS may be clinically relevant since reduced numbers could insufficiently activate populations required for controlling disease activity: this has been shown for the functional activities of NKR+ T-cells in tumour immunity [58]. The gene discussed is KLRB1; the disease is neoplasm.